Seres Therapeutics reported a net loss of $19.9 million for Q1 2026, down from a net income of $32.7 million in Q1 2025, mainly due to the absence of a $50 million payment from Nestlé related to the VOWST sale. The company is progressing its live biotherapeutic pipeline, including SER-155 for immune checkpoint inhibitor-related enterocolitis and bloodstream infection prevention in blood cancer patients, and SER-603 for inflammatory bowel disease. Clinical data from an investigator-sponsored trial of SER-155 is expected soon, which could expand its therapeutic applications. Seres is actively seeking partnerships and funding to support further development and extend its cash runway beyond Q3 2026.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
Infrastructure Capital Advisors announced the first monthly dividend of $1 per share for its Infrastructure Capital Nasdaq Option Income ETF (QVOL), targeting an annualized distribution rate of 12-15%. The firm also declared monthly dividends for its...
G-III Apparel Group announced a quarterly cash dividend of $0.10 per share, payable on July 8, 2026, to shareholders of record as of June 22, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. G-III is ...
